March 11, 2025 01:39 PM EDTUpdated 04:22 PM

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Nicole DeFeudis

Editor

Merck convinced a federal judge to toss claims alleging that it failed to properly warn patients of potential risks related to its Gardasil HPV vaccine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Nicole DeFeudis

Editor

Sign up to read this article for free.

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Bristol Myers buys out cell therapy partner 2seventy bio

Corrected: Merck opens billion-dollar US facility to make Gardasil

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

Obesity drug development—still room to grow

Mer­ck scores a win in Gar­dasil cas­es af­ter judge says plain­tiffs’ ev­i­dence ‘falls far short’

Nicole DeFeudis

Editor

Sign up to read this article for free.

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Bris­tol My­ers buys out cell ther­a­py part­ner 2sev­en­ty bio

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

Obe­si­ty drug de­vel­op­ment—still room to grow

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Bristol Myers buys out cell therapy partner 2seventy bio

Corrected: Merck opens billion-dollar US facility to make Gardasil

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

Obesity drug development—still room to grow